Latest Articlesddd

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

June 25, 2019 0

Krystal Biotech Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare …

The FDA Approved AMAG Pharmaceuticals’ Product Vyleesi™ for Premenopausal Women with Acquired Generalized Hypoactive Sexual Desire Disorder

June 24, 2019 0

AMAG Pharmaceuticals’ Vyleesi™ was Approved The U.S. Food and Drug Administration (FDA) approved AMAG Pharmaceuticals’ (AMAG) product …

Treating Hemoglobinopathies

June 21, 2019 0

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …

News From Four Biotech Companies and Several Treatments

June 19, 2019 0

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has …

Pfizer to Acquire Array Biopharma at $48 a Share

June 17, 2019 0

Pfizer to Acquire Array Pfizer (PFE) announced that it has agreed to acquire Array Biopharma (ARRY) …

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

June 14, 2019 0

Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird …

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

June 13, 2019 3

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology …

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment

June 12, 2019 0

Good News about Novartis’ Cosentyx® for Psoriatic Arthritis Novartis (NVS) has good news for Cosentyx®. Data emerging out …

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Why Vertex’s and CRISPR Therapeutics’ Stocks Are Rallying

June 7, 2019 0

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene …

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

June 6, 2019 0

AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology …

bluebird bio Announces a European Conditional Approval of Its Gene Therapy ZYNTEGLO™ for Transfusion-Dependent β-Thalassemia  

June 4, 2019 0

Zynteglo™ from bluebird bio Gets European Conditional Approval European marketing authorization for Zynteglo follows the fastest …

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

June 4, 2019 0

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is …

Cara Therapeutics: More Positive Results from the Korsuva Product Trial for Hemodialysis Patients’ Pruritis

May 30, 2019 0

Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, …

Recent News from Incyte, Merck and Nektar

May 29, 2019 0

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

May 24, 2019 0

Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …

Vertex: Good News and Good Decisions

May 23, 2019 0

Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered …

Array BioPharma: Great News and a Learning Experience

May 21, 2019 0

Great News for Array BioPharma  Array BioPharma (ARRY) announced positive results from the interim analysis of …

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

May 21, 2019 0

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …